{"id":71609,"date":"2026-08-04T12:16:51","date_gmt":"2026-08-04T04:16:51","guid":{"rendered":"https:\/\/flcube.com\/?p=71609"},"modified":"2026-08-04T12:16:52","modified_gmt":"2026-08-04T04:16:52","slug":"cspc-pharmaceutical-launches-phase-ib-ii-trial-of-novel-sys6090-fusion-protein-for-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71609","title":{"rendered":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that a Phase Ib\/II clinical trial of <strong>SYS6090 combination therapy<\/strong> for the treatment of <strong>colorectal cancer<\/strong> has been officially initiated at the first study center in China.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group Limited (HKG: 1093)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYS6090<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Recombinant fully human anti-PD-1 and IL-15 fusion protein<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Colorectal cancer (combination therapy)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ib\/II<\/td><\/tr><tr><td><strong>Initiation Date<\/strong><\/td><td>3 Aug 2026<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>First study center in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type<\/strong>: Recombinant fully human anti-PD-1 and IL-15 fusion protein<\/li>\n\n\n\n<li><strong>Left Arm Function<\/strong>: Targets PD-1\u2013positive tumor-infiltrating immune cells to block immunosuppressive function caused by PD-1\/PD-L1 interaction<\/li>\n\n\n\n<li><strong>Right Arm Function<\/strong>: Binds to IL-15 receptor, activating downstream signaling pathways to promote activation and proliferation of relevant immune cells<\/li>\n\n\n\n<li><strong>Preclinical Results<\/strong>: Significantly inhibits tumor growth, favorable safety and tolerability profile, superior efficacy compared to other anti-PD-1 monoclonal antibodies and IL-15 agents<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Colorectal cancer represents the second most common cause of cancer-related deaths worldwide, with particularly high incidence rates in Asia. Current treatment options often face challenges with drug resistance and limited efficacy in later-stage disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SYS6090&#8217;s dual mechanism of action addresses two critical aspects of cancer immunotherapy: overcoming immunosuppression in the tumor microenvironment while simultaneously enhancing immune cell activation and proliferation. This innovative approach could potentially overcome limitations of current monotherapies.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Colorectal Cancer Burden<\/strong>: Approximately 1.9 million new cases diagnosed annually worldwide<\/li>\n\n\n\n<li><strong>China Incidence<\/strong>: Over 550,000 new cases annually, representing one of the highest incidence rates globally<\/li>\n\n\n\n<li><strong>Current Treatment Limitations<\/strong>: Significant unmet medical need for patients who develop resistance to existing therapies<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: SYS6090 represents CSPC&#8217;s entry into the growing immuno-oncology combination therapy market<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Successful development could position CSPC as a leader in innovative colorectal cancer therapeutics in China and internationally<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-company-pipeline-strategy\" class=\"wp-block-heading\">Company Pipeline Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This milestone marks a significant advancement in our oncology pipeline,&#8221; said a CSPC spokesperson. &#8220;Colorectal cancer remains a major health challenge in China and globally, with substantial unmet medical needs for patients who develop resistance to existing therapies. Our team has designed SYS6090 to potentially overcome these limitations through its unique dual mechanism of action.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CSPC Pharmaceutical maintains a robust pipeline of over 300 products in various stages of development, with particular focus on oncology, metabolic diseases, and anti-infective therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for SYS6090. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080303654_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080303654_c.\"><\/object><a id=\"wp-block-file--media-5302c3e1-8056-4b5a-8218-31ee4691d99d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080303654_c.pdf\">2026080303654_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080303654_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5302c3e1-8056-4b5a-8218-31ee4691d99d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,62,171,855],"class_list":["post-71609","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71609\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71609\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T04:16:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T04:16:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Launches Phase Ib\\\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer\",\"datePublished\":\"2026-08-04T04:16:51+00:00\",\"dateModified\":\"2026-08-04T04:16:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71609#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71609\",\"name\":\"CSPC Pharmaceutical Launches Phase Ib\\\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-04T04:16:51+00:00\",\"dateModified\":\"2026-08-04T04:16:52+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\\\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71609\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71609#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Launches Phase Ib\\\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71609","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.","og_url":"https:\/\/flcube.com\/?p=71609","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-04T04:16:51+00:00","article_modified_time":"2026-08-04T04:16:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71609#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71609"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer","datePublished":"2026-08-04T04:16:51+00:00","dateModified":"2026-08-04T04:16:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71609"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71609#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71609","url":"https:\/\/flcube.com\/?p=71609","name":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-04T04:16:51+00:00","dateModified":"2026-08-04T04:16:52+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib\/II clinical trial of SYS6090 combination therapy for the treatment of colorectal cancer has been officially initiated at the first study center in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71609#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71609"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71609#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Launches Phase Ib\/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71609"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71609\/revisions"}],"predecessor-version":[{"id":71612,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71609\/revisions\/71612"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}